/ 2 items

#CNTX↓

OVID/ 12/22/2025 · 10:36 AM

Biotech Stocks Update: ZBIO, SPRB, CNTX, OVID Ratings

Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.

CNTX/ 10/02/2025 · 10:17 AM

Context Therapeutics: A Promising Cancer Drug Developer

A hidden cancer company, Context, got a top rating. Its ovarian cancer drug, CTIM-76, has key data coming in 2026.